FABTECH
Fabtech Technologies Limited
EPC solutions for pharma and life sciences industries
Healthcare›Healthcare›Healthcare Equipment & Supplies›Medical Equipment & Supplies
fabtechnologies.com(opens the company website in a new tab)Key metrics
Price as of 2026-10-16
Full years shown; sign in free for the trailing twelve months. Learn about these metrics →
Price & valuation
Share price and valuation multiples (P/E, P/B and more) over time.
Loading price history…
Compare with peers
Loading peers…
What you need to know
Fabtech Technologies (Fabtech) designs and builds turnkey pharmaceutical plants, including cleanrooms, air-handling systems and water and utility systems, mainly for drug makers in emerging markets such as the Middle East, Africa and Southeast Asia.
Company snapshot
6thBy market cap
Ranked among 8 companies in Medical Equipment & Supplies.
What we see
- ✓Debt-to-equity of 0.10x — the company is largely funded by its own money, not borrowed funds.
- ✗Only 23% of operating profit came in as cash over the last three years — much of it is tied up in unpaid bills or stock.
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Sales | 68 Cr | 121 Cr | 63 Cr | 159 Cr | 75 Cr |
| Operating expenses (approx.) | 74 Cr | 91 Cr | 74 Cr | 136 Cr | 71 Cr |
| EBITDA | -6 Cr | 30 Cr | -11 Cr | 22 Cr | 4 Cr |
| OPM % | -9.1% | 25.1% | -18.3% | 14.0% | 5.7% |
| Other income | 0.95 Cr | 3 Cr | 7 Cr | 10 Cr | 3 Cr |
| Interest | 1 Cr | 1 Cr | 0.87 Cr | 0.88 Cr | 0.86 Cr |
| Depreciation | 1 Cr | 1 Cr | 1 Cr | 1 Cr | 1 Cr |
| Profit before tax | -6 Cr | 31 Cr | -7 Cr | 30 Cr | 5 Cr |
| Tax % | 1.1% | 10.1% | 15.1% | 26.2% | 19.5% |
| Net profit | -6 Cr | 28 Cr | -6 Cr | 22 Cr | 4 Cr |
| EPS (₹) | ₹-1.89 | ₹8.68 | ₹-1.56 | ₹5.75 | ₹0.95 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 194 Cr | 226 Cr | 327 Cr | 411 Cr | Sign in free for the trailing twelve months |
| Operating expenses (approx.) | 171 Cr | 192 Cr | 289 Cr | 376 Cr | Sign in free for the trailing twelve months |
| EBITDA | 23 Cr | 34 Cr | 38 Cr | 35 Cr | Sign in free for the trailing twelve months |
| OPM % | 11.7% | 15.0% | 11.5% | 8.5% | Sign in free for the trailing twelve months |
| Other income | 6 Cr | 4 Cr | 9 Cr | 21 Cr | Sign in free for the trailing twelve months |
| Interest | 3 Cr | 2 Cr | 2 Cr | 4 Cr | Sign in free for the trailing twelve months |
| Depreciation | 2 Cr | 2 Cr | 3 Cr | 5 Cr | Sign in free for the trailing twelve months |
| Profit before tax | 28 Cr | 36 Cr | 60 Cr | 48 Cr | Sign in free for the trailing twelve months |
| Tax % | 22.1% | 23.9% | 23.1% | 20.5% | Sign in free for the trailing twelve months |
| Net profit | 22 Cr | 27 Cr | 46 Cr | 38 Cr | Sign in free for the trailing twelve months |
| EPS (₹) | ₹6.74 | ₹8.43 | ₹14.34 | ₹10.00 | Sign in free for the trailing twelve months |
| Dividend payout % | — | — | — | 0.0% | Sign in free for the trailing twelve months |
The latest four quarters added up, next to each full year
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 3 Cr | 3 Cr | 32 Cr | 44 Cr |
| Reserves | 86 Cr | 129 Cr | 141 Cr | 375 Cr |
| Borrowings | 34 Cr | 10 Cr | 55 Cr | 43 Cr |
| Other liabilities | 91 Cr | 127 Cr | 199 Cr | 191 Cr |
| Total liabilities | 214 Cr | 269 Cr | 427 Cr | 654 Cr |
| Fixed assets (net) | 4 Cr | 6 Cr | 56 Cr | 55 Cr |
| CWIP | — | — | — | — |
| Investments | 20 Cr | 21 Cr | 15 Cr | 26 Cr |
| Loans & advances | — | — | — | 0.13 Cr |
| Inventories | 17 Cr | 29 Cr | 59 Cr | 21 Cr |
| Trade receivables | 99 Cr | 97 Cr | 151 Cr | 204 Cr |
| Cash & bank | 11 Cr | 29 Cr | 9 Cr | 87 Cr |
| Other assets | 63 Cr | 88 Cr | 136 Cr | 260 Cr |
| Total assets | 214 Cr | 269 Cr | 427 Cr | 654 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operating activity | -14 Cr | 60 Cr | -36 Cr | 0.48 Cr |
| Cash from investing | 2 Cr | -30 Cr | -20 Cr | -112 Cr |
| Cash from financing | 12 Cr | -12 Cr | 36 Cr | 190 Cr |
| Net cash flow | -0.03 Cr | 18 Cr | -20 Cr | 78 Cr |
| Free cash flow (OCF − Capex) | -14 Cr | 59 Cr | -61 Cr | -4 Cr |
Ratios
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROCE % | 24.7% | 26.6% | 27.5% | 11.3% |
| ROE % | 24.4% | 20.6% | 26.8% | 9.1% |
| Debtor days | 187 | 156 | 168 | 181 |
| Inventory days | 32 | 26363 | 110682 | 19 |
| Days payable | 101 | 58592 | 184055 | 93 |
| Cash conversion cycle | 118 | -32073 | -73204 | 107 |
| OCF / EBITDA % | -61.4% | 178.2% | -95.9% | 1.4% |
| OCF / EBITDA % (3 years) | — | — | 11.0% | 23.2% |
| Debt / equity | 0.39 | 0.07 | 0.32 | 0.10 |
| Current ratio | 1.48 | 1.70 | 1.37 | 2.50 |
| Net debt / EBITDA | 1.05 | -0.56 | 1.21 | -1.26 |